Sulaiman et al., 2018 demonstrated that TNBC showed overexpression of mTORC1 and HDAC as compared to luminal breast cancer, and that the combination of mTORC1 and HDAC inhibitors provided a synergistic activity against TNBC [145]. This evidence concerns the gene HDAC9 and breast carcinoma.